Mark Krul – Startup Investor Profile

Mark Krul is the Partner/Co-Founder of Aglaia Biomedical Ventures BV, an oncology specialist investor focused on early-stage breakthrough inventions. Aglaia invests in oncology and novel tools in contemporary drug development. The target fund size is $80-$100 million, with investments in 10-15 high-potential oncology start-ups. Mark Krul is actively involved as a Founder and Director, supporting early-stage companies in drug development as a board member. His geographical preference spans across the Netherlands, focusing on oncology advancements. Previous investments include boards at MIMETAS, Cristal Therapeutics, and others. Mark Krul holds a Ph.D. in Medical Biology from Utrecht University and has a comprehensive background in anticancer drug development.

Location: Netherlands

Country: Netherlands

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.aglaia-oncology.com/team/

AI Reasoning: Found a news item on Aglaia’s site showing involvement with MIMETAS dated July 11, 2024. That investment/activity is 16 months before Nov 1, 2025 – however the more relevant activity is evidence of continued involvement with portfolio companies; additional site news and portfolio mention investment in MIMETAS (startup: MIMETAS). The last known dated activity July 11, 2024 is 1 year 3 months ago. Given that, classification would be ‘low-active’. But earlier LinkedIn/Golden entries indicate ongoing roles and Aglaia co-led financing in Cristal Therapeutics in Jan 2017. Since the most recent verifiable investment-related activity is July 11, 2024 (MIMETAS), which is more than 12 months ago, the correct tag is low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.